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Introduction
Stem cells have attracted much attention recently be-
cause of their unique biological behaviors and attractive
clinical usages. CD34+ hematopoietic stem cells (HSCs),
for example, have been used for clinical stem cell trans-
plantation [1]. Clinically, HSCs can be obtained from
three different anatomic locations: bone marrow (BM),
peripheral blood (PB), and umbilical cord blood 
(CB). To improve our ability to utilize various HSCs, it
is necessary to understand the differences between
these stem cells and to decipher their underlying 
mechanisms.
In humans, most HSCs and precursors express CD34
antigen while being negative for the CD38 hematopoi-
etic lineage marker [2,3]. The CD34+ CD38− popula-
tion can be divided into long-term and short-term
functional HSCs with surface makers CD34+ CD33−
CD38− Rholow and CD34+ CD33− CD38– Rhohigh,
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SUMMARY
Objective: Somatic CD34+ CD38− stem cells can differentiate into cells of hematopoietic and endothelial lineages
and have been clinically used to treat diseases. These stem cells can be obtained from cord blood (CB), bone
marrow or granulocyte-macrophage colony-stimulating factor–mobilized peripheral blood. Unmasking genes
differentially expressed in hematopoietic stem cells (HSCs) from different anatomic locations can improve our
understanding of their basic biological features and help in clinical decision making when applying different HSCs.
Materials and Methods: We performed microarray analysis on human CD34+ CD38− HSCs isolated from CB,
bone marrow and peripheral blood. Systems biology and advanced bioinformatics tools were used to better
understand the biological modules and genetic networks accompanying each HSC subtype.
Results: We identified HSC genes differentially expressed in various HSCs and found them to be involved in crit-
ical biological processes such as cell cycle regulation, cell motility, and endogenous antigen presentation.
Among these three HSC types, HSCs from CB expressed the fewest rejection and immune response-associated
genes, thereby showing the best potential as a transplantation source. Analysis of HSC-enriched genes using
systems biology tools revealed a complex genetic network functioning in different CD34+ CD38− cells, in which
several genes act as hubs, such as MYC in CB HSCs and hepatic growth factor in bone marrow HSCs, to maintain
the stability or connectivity of the whole network.
Conclusion: This study provides the foundation for a more detailed understanding of CD34+ CD38− HSCs from
different sources, and reveals the potentials of different HSCs for different clinical applications. [Taiwan J Obstet
Gynecol 2009;48(4):356–369]
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respectively [4]. Recently, the CD133 antigen has also
been used for HSC isolation [5,6]. The gene expression
patterns of different human CD34+ HSCs isolated
from various anatomic locations have been character-
ized by genomic analyses, which revealed genes involved
in self-renewal, differentiation and lineage choice [2,7].
However, the assignment of biological significance to
the filtered genes or even to each HSC type remains
difficult. In this post-genomics era, modern bioinfor-
matics and systems biology tools can help to predict
biological behaviors or interactions of gene products.
Deductions of de novo gene relationships by exploratory
computational tools and systems biology algorithms
can provide a systematic approach to discovering
novel molecular events and relationships [8–10]. The
combination of microarray and computational results
enables biologists to speed up their research and to
analyze data.
The aims of this study were to identify the genes re-
sponsible for stem cell properties in various CD34+
CD38− HSCs and to reveal the biological differences
between them using systems biology approaches. We
compared the gene expression profiles of HSCs from
various anatomic locations. Our analysis revealed that
CD34+ CD38− HSCs from different sources possess
different biological properties and hence hold differ-
ent application potentials.
Materials and Methods
CD34+ CD38− cells and primary microvascular
endothelial cells (MVECs)
Human CD34+ CD38− cells were isolated from BM, PB or
CB of healthy individuals (Poietics; Lonza Group Ltd.,
Basel, Switzerland). Human MVECs (Clonetics; Lonza
Group Ltd.) were cultured in EGM-2 MV BulletKit
medium (Lonza Group Ltd.).
RNA isolation and real-time polymerase chain
reaction (PCR)
Total messenger RNA was extracted using an RNeasy
mini kit (catalog no. 74106; Qiagen, Hilden, Germany)
and 100 ng to 1 μg of total RNA was reverse transcribed
using a First cDNA Synthesis Kit (catalog no. K1612;
Fermentas, Glen Burnie, MD, USA). For quantitative
real-time PCR analysis, the human pre-messenger RNA
sequence was obtained from the National Center for
Biotechnology Information AceView program (http://
www.ncbi.nlm.nih.gov/AceView/). All primers were de-
signed across introns in the Primer3 Web site
(http://frodo.wi.mit.edu/primer3/) or Primer Express
software (Applied Biosystems, Foster City, CA, USA).
Thermodynamics and primer specificity analyses were
performed using the Vector NTI suite (Invitrogen,
Carlsbad, CA, USA) and the National Center for
Biotechnology Information reverse e-PCR program
( h t t p : / / w w w . n c b i . n l m . n i h . g o v / s u t i l s / e -
pcr/reverse.cgi/). Real-time PCR reactions were per-
formed using Maxima SYBR Green qPCR Master Mix
(catalog no. K0222; Fermentas), and specific prod-
ucts were detected and analyzed using a StepOne
sequence detector (Applied Biosystems). The expres-
sion level of each gene was normalized to the expres-
sion level of glyceraldehyde 3-phosphate
dehydrogenase.
Array probe preparation, data analysis, and 
functional network analyses
Total RNA collection, complementary RNA probe prep-
aration, array hybridization and data analysis were
performed as previously described [10,11]. Expression
profiles of CD34+ CD38− HSCs, MVECs and PB mono-
nuclear cells were implemented using the Affymetrix
HG-U133A chip (Affymetrix, Santa Clara, CA, USA).
Gene annotation enrichment analysis was performed
using the DAVID 2008 tool (http://david.abcc.ncifcrf.
gov/) [12]. EASE score, a Fisher’s exact test-based
scoring system, was used to calculate p values to deter-
mine the probability of the number of genes being
specifically associated (enriched) with a given gene on-
tology (GO) term or occurring by random chance. The
Ingenuity Pathway Analysis (IPA) Web tool developed
by the Ingenuity Co. (http://www.ingenuity.com/) was
used to construct functional regulatory networks of
gene profiles. IPA uses the Ingenuity Pathways Knowl-
edge Base to identify known interactions between focus
genes as well as other genes that are not present in the
gene list. IPA then determines a statistical score for each
network according to the fit of the network to the set
of focus genes. The score is the negative log of p and
denotes the likelihood of the focus genes in the net-
work being found together by chance.
Results
Molecular signatures of various CD34+ CD38− HSCs
To access molecular signature genes for HSCs, we
obtained human CD34+ CD38− HSCs from umbilical
CB. Abundant expression of known “stemness” or pre-
cursor genes (including GATA2, GATA1 and RUNX1) in
CD34+ CD38− cells were verified by quantitative PCR
(Figure 1A).
To compare the gene expression profiles and bio-
logical variations between HSCs from different anatomic
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locations, we also isolated CD34+ CD38− HSCs from
BM and granulocyte-macrophage colony-stimulating
factor–mobilized PB from healthy individuals. The gene
expression profiles of various HSCs were determined
and compared. The gene expression profiles of these
three cell types were implemented at least in triplicate
using the Affymetrix HG-U133A chip. According to the
statistical pipeline used [10,11,13], genes differentially
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Figure 1. Transcriptome analysis of hematopoietic stem cells (HSCs) isolated from different anatomic locations. (A) Enriched
expression of stemness and precursor genes in isolated HSCs. CD34+ CD38− HSCs isolated by magnetic beads were subjected
to total RNA isolation and quantitative polymerase chain reaction analysis. Primary microvascular endothelial cells were used
as a mature progeny control. Mean expression levels of target genes were compared with that of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) control. (B) Multidimensional scaling (MDS) plots using the whole transcriptome (upper) or fil-
tered genes (lower) show the discrimination ability of the obtained molecular signature for cell groups. Each spot represents
a single array sample. BM = bone marrow; CB = cord blood; PB = peripheral blood. (C) A heat map shows genes differentially
expressed in different CD34+ CD38− HSCs. Genes in red, increased expression; in blue, decreased.
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expressed between each cell type (the molecular signa-
ture) were identified. A total of 910 probe sets were
uniquely upregulated in CB HSCs, 450 in BM HSCs,
and 912 in PB HSCs (with a positive false discovery
rate threshold, q < 0.005). In contrast, 220 probe sets
were uniquely downregulated in CB HSCs, 851 in BM
HSCs, and 1287 in PB HSCs (q < 0.005).The discrimi-
nation ability of these genes was assessed using multi-
dimensional scaling (Figure 1B). A gene expression heat
map for these genes indicated their unique expression
in different CD34+ CD38− HSCs (Figure 1C).
The top 50 genes most strongly expressed or re-
pressed in CD34+ CD38− CB HSCs are listed in Tables
1 and 2, respectively. The top 50 genes in BM HSCs
and PB HSCs are listed in Tables 3 and 4, respectively.
In CB HSCs, genes involved in transplant rejection
(such as HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-
DQA1 and HLA-DQB1) or immune response (such as
interferon-induced proteins and CXCR4) were strongly
downregulated (labeled with asterisks, Table 2).
In BM HSCs, genes involved in cell survival (such 
as the baculoviral IAP repeat-containing 5, also known
as survivin [14]) and cell cycle progression (such as
cyclin A2) were most active (Table 3). In contrast, in
PB HSCs, cell cycle inhibitors such as cyclin-dependent
kinase inhibitor 1C (CDKN1C; also known as p57KIP2)
were overexpressed (Table 4), suggesting a less active
cell cycle or cell proliferating condition in HSCs from 
PB. PB HSCs expressed the highest levels of PROM1
(CD133) gene, a marker of HSCs and other stem cell
types, such as colon epithelial stem cells [13], indi-
cating a higher stemness status of this HSC subtype.
PB HSCs also expressed more genes involved in en-
dothelial (vascular endothelial growth factor A) and
megakaryocytic (RUNX1 [15]) differentiation, indi-
cating their multipotency. Ezrin, a cell membrane–
cytoskeleton cross-linker that can increase cellular
motility [16,17] was also strongly expressed in PB
HSCs (Table 4).
Functional grouping reveals unique biological
properties in each HSC subtype
Gene signatures provided indications of the functional
differences among these three HSC subtypes. To provide
quantitative evidence and to gain more insights into the
functional consequences of differential gene expression
patterns, probe sets enriched or repressed in each HSC
subtype were subjected to the GO database search [18]
to find statistically overrepresented functional groups
within each gene list. The DAVID 2008 Web-based
tool, a graph theory evidence-based method to agglo-
merate gene/protein identifiers [12], was used for 
this task.
The GO categories of biological processes statisti-
cally overrepresented (p < 0.05) are shown in Figure 2.
The predominant processes in CB HSCs included those
pertaining to DNA repair, nuclear messenger RNA splic-
ing and export, and ribosomal RNA or transfer RNA pro-
cessing (Figure 2A). In contrast, response to stress and
endogenous antigen processing and presentation path-
ways were less active in CB-derived HSCs (Figure 2A).
Of the three HSC subtypes, HSCs from BM possessed
the largest number of genes involved in cell cycle pro-
gression (especially those involved in mitosis and spin-
dle biogenesis) and transplant rejection (i.e. major
histocompatibility complex class I endogenous antigen
processing and presentation). BM HSCs also possessed
the fewest genes involved in cell cycle arrest and cellu-
lar migration, indicating an active proliferation yet sta-
tionary property of HSCs inside BM (Figure 2B). HSCs
from PB expressed the most genes involved in cell mo-
tility, reflecting the fact that they were collected after
granulocyte-macrophage colony-stimulating factor mo-
bilization (Figure 2C). PB HSCs may also replicate less
and participate more in immune response or angio-
genesis, because the genes involved in these biological
processes were the most differentially expressed in PB
HSCs (Figure 2C).
Coordinated changes in functional networks of 
CB HSC upregulated genes
The above genomics data suggest different biological
potentials of HSC subtypes isolated from various anat-
omic locations. Increasing evidence shows that genes
do not act individually but collaborate in genetic net-
works. To better understand how genes enriched in each
population of CD34+ CD38− cells are related and how
they relate to cellular function, we performed genetic
network analysis for signature genes using the IPA Web
tool and the Ingenuity knowledge database. The knowl-
edge base behind IPA summarizes known molecular
interactions evidenced in the published literature. The
term network in IPA does not refer to a biological or
canonical pathway with a distinct function (i.e. angio-
genesis) but is, rather, a reflection of all the interac-
tions of a given protein as defined in the literature (see
“Materials and Methods”).
In CB HSCs, a major network consisting of 258
genes was identified (Figure 3A). This network revealed
genes whose roles may be more crucial than others in
CB HSCs. GATA1, MYC, NMYC, JUN and YWHAZ are
the “hub” genes (genes involved in the greatest num-
ber of interactions with other components) that either
preserve the stability of the whole network or link sub-
modules in the same network to each other (Figure
3A). These hub genes are all involved in the regulation
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Table 1. Top 50 genes enriched in cord blood CD34+ CD38– hematopoietic stem cells
Probe set ID UniGene ID Gene title Gene symbol Location
203196_at Hs.508423 ATP-binding cassette, sub-family C (CFTR/MRP, member 4) ABCC4 chr13q32
212224_at Hs.76392 Aldehyde dehydrogenase 1 family, member A1 ALDH1A1 chr9q21.13
204446_s_at Hs.89499 Arachidonate 5-lipoxygenase ALOX5 chr10q11.2
204174_at Hs.507658 Arachidonate 5-lipoxygenase-activating protein ALOX5AP chr13q12
203304_at Hs.533336 BMP and activin membrane-bound inhibitor BAMBI chr10p12.3-
homolog (Xenopus laevis) p11.2
202391_at Hs.201641 Brain abundant, membrane attached signal protein 1 BASP1 chr5p15.1-p14
215440_s_at Hs.184736 BEX family member 4 BEX4 chrXq22.1-q22.3
218829_s_at Hs.709651 Chromodomain helicase DNA binding protein 7 CHD7 chr8q12.2
201735_s_at Hs.481186 Chloride channel 3 CLCN3 chr4q33
205624_at Hs.646 Carboxypeptidase A3 (mast cell) CPA3 chr3q21-q25
205159_at Hs.592192 Colony stimulating factor 2 receptor, beta, CSF2RB chr22q13.1
low-affinity (granulocyte-macrophage)
218858_at Hs.112981 DEP domain containing 6 DEPDC6 chr8q24.12
219799_s_at Hs.179608 Dehydrogenase/reductase (SDR family) member 9 DHRS9 chr2q31.1
209560_s_at Hs.533717 Delta-like 1 homolog (Drosophila) DLK1 chr14q32
204720_s_at Hs.647643 DnaJ (Hsp40) homolog, subfamily C, member 6 DNAJC6 chr1pter-q31.3
201123_s_at Hs.534314 Eukaryotic translation initiation factor 5A EIF5A chr17p13-p12
220643_s_at Hs.173438 Fas apoptotic inhibitory molecule FAIM chr3q22.3
204417_at Hs.513439 Galactosylceramidase GALC chr14q31
204115_at Hs.83381 Guanine nucleotide binding protein (G protein), GNG11 chr7q21
gamma 11
215780_s_at Hs.436687 SET nuclear oncogene SET chr9q34
207067_s_at Hs.1481 Histidine decarboxylase HDC chr15q21-q22
203394_s_at Hs.250666 Hairy and enhancer of split 1, (Drosophila) HES1 chr3q28-q29
208025_s_at Hs.505924 High mobility group AT-hook 2 HMGA2 chr12q15
200679_x_at Hs.712556 High mobility group box 1 HMGB1 chr13q12
207194_s_at Hs.706750 Intercellular adhesion molecule 4 ICAM4 chr19p13.2-cen
(Landsteiner-Wiener blood group)
211953_s_at Hs.643743 Importin 5 IPO5 chr13q32.2
218170_at Hs.483296 Isochorismatase domain containing 1 ISOC1 chr5q22.1-q33.3
205885_s_at Hs.694732 Integrin, alpha 4 (antigen CD49D, alpha 4 ITGA4 chr2q31.3
subunit of VLA-4 receptor)
221558_s_at Hs.555947 Lymphoid enhancer-binding factor 1 LEF1 chr4q23-q25
209204_at Hs.436792 LIM domain only 4 LMO4 chr1p22.3
201669_s_at Hs.519909 Myristoylated alanine-rich protein kinase C substrate MARCKS chr6q22.2
212473_s_at Hs.501928 Microtubule associated monooxygenase, calponin and MICAL2 chr11p15.3
LIM domain containing 2
212604_at Hs.154655 Mitochondrial ribosomal protein S31 MRPS31 chr13q14.11
212372_at Hs.16355 Myosin, heavy chain 10, non-muscle MYH10 chr17p13
205006_s_at Hs.60339 N-myristoyltransferase 2 NMT2 chr10p13
208857_s_at Hs.279257 Protein-L-isoaspartate (D-aspartate) O-methyltransferase PCMT1 chr6q24-q25
218676_s_at Hs.285218 Phosphatidylcholine transfer protein PCTP chr17q21-q24
206726_at Hs.128433 Prostaglandin D2 synthase, hematopoietic PGDS chr4q22.3
209318_x_at Hs.444975 Pleiomorphic adenoma gene-like 1 PLAGL1 chr6q24-q25
213241_at Hs.584845 Plexin C1 PLXNC1 chr12q23.3
219485_s_at Hs.522752 Proteasome (prosome, macropain) 26S subunit, PSMD10 chrXq22.3
non-ATPase, 10
206157_at Hs.591286 Pentraxin-related gene, rapidly induced by IL-1 beta PTX3 chr3q25
212012_at Hs.332197 Peroxidasin homolog (Drosophila) PXDN chr2p25
218668_s_at Hs.119889 RAP2C, member of RAS oncogene family RAP2C chrXq25
202988_s_at Hs.75256 Regulator of G-protein signaling 1 RGS1 chr1q31
205352_at Hs.478153 Serpin peptidase inhibitor, clade I (neuroserpin), SERPINI1 chr3q26.1
member 1
203775_at Hs.489190 Solute carrier family 25, member 13 (citrin) SLC25A13 chr7q21.3
220059_at Hs.435579 Signal transducing adaptor family member 1 STAP1 chr4q13.2
201147_s_at Hs.701968 TIMP metallopeptidase inhibitor 3 TIMP3 chr22q12.1
219478_at Hs.36688 WAP four-disulfide core domain 1 WFDC1 chr16q24.3
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Table 2. Top 50 genes downregulated in cord blood CD34+ CD38– hematopoietic stem cells
Probe set ID UniGene ID Gene title Gene symbol Location
209160_at Hs.78183 Aldo-keto reductase family 1, member C3 AKR1C3 chr10p15-p14
207848_at Hs.89648 Arginine vasopressin AVP chr20p13
205681_at Hs.227817 BCL2-related protein A1 BCL2A1 chr15q24.3
201641_at Hs.118110 Bone marrow stromal cell antigen 2 BST2 chr19p13.2
208683_at Hs.350899 Calpain 2, (m/II) large subunit CAPN2 chr1q41-q42
209732_at Hs.85201 C-type lectin domain family 2, member B CLEC2B chr12p13-p12
213415_at Hs.655445 Chloride intracellular channel 2 CLIC2 chrXq28
217028_at Hs.593413 Chemokine (C-X-C motif) receptor 4 CXCR4* chr2q21
218094_s_at Hs.655055 Dysbindin domain containing 2 DBNDD2 chr20q13.12
209383_at Hs.505777 DNA-damage-inducible transcript 3 DDIT3 chr12q13.1-q13.2
201324_at Hs.436298 Epithelial membrane protein 1 EMP1 chr12p12.3
205767_at Hs.115263 Epiregulin EREG chr4q13.3
212998_x_at Hs.728 Major histocompatibility complex, class II, DQ beta 1 HLA-DQB1* chr14q24-q31
206082_at Hs.654480 HLA complex P5 HCP5* chr6p21.3
213932_x_at Hs.181244 Major histocompatibility complex, class I, A HLA-A* chr6p21.3
209140_x_at Hs.549053 Major histocompatibility complex, class I, B HLA-B* chr6p21.3
208812_x_at Hs.654404 Major histocompatibility complex, class I, C HLA-C* chr6p21.3
213537_at Hs.347270 Major histocompatibility complex, class II, DP alpha 1 HLA-DPA1* chr6p21.3
213831_at Hs.387679 Major histocompatibility complex, class II, DQ alpha 1 HLA-DQA1* chr6p21.3
211654_x_at Hs.409934 Major histocompatibility complex, class II, DQ beta 1 HLA-DQB1* chr6p21.3
200599_s_at Hs.192374 Heat shock protein 90kDa beta (Grp94), member 1 HSP90B1* chr12q24.2-q24.3
214453_s_at Hs.82316 Interferon-induced protein 44 IFI44* chr1p31.1
204439_at Hs.389724 Interferon-induced protein 44-like IFI44L* chr1p31.1
204415_at Hs.511731 Interferon, alpha-inducible protein 6 IFI6* chr1p35
201601_x_at Hs.458414 Interferon induced transmembrane protein 1 (9-27) IFITM1* chr11p15.5
205376_at Hs.658245 Inositol polyphosphate-4-phosphatase, type II, INPP4B chr4q31.21
105kDa
204698_at Hs.459265 Interferon stimulated exonuclease gene 20 kDa ISG20* chr15q26
213281_at Hs.525704 Jun oncogene JUN chr1p32-p31
203542_s_at Hs.150557 Kruppel-like factor 9 KLF9 chr9q13
214056_at Hs.632486 Myeloid cell leukemia sequence 1 (BCL2-related) MCL1 chr1q21
212509_s_at Hs.250723 Matrix-remodelling associated 7 MXRA7 chr17q25.1-q25.2
218966_at Hs.487036 Myosin VC MYO5C chr15q21
202074_s_at Hs.332706 Optineurin OPTN chr10p13
202464_s_at Hs.195471 6-Phosphofructo-2-kinase/fructose-2, PFKFB3 chr10p14-p15
6-biphosphatase 3
204279_at Hs.654585 Proteasome (prosome, macropain) subunit, PSMB9 chr6p21.3
beta type, 9
204897_at Hs.199248 Prostaglandin E receptor 4 (subtype EP4) PTGER4 chr5p13.1
204070_at Hs.17466 Retinoic acid receptor responder RARRES3 chr11q23
(tazarotene induced) 3
212044_s_at Hs.523463 Ribosomal protein L27a RPL27A chr11p15
214041_x_at Hs.433701 Ribosomal protein L37a RPL37A chr2q35
202028_s_at Hs.380953 Ribosomal protein L38 RPL38 chr17q23-q25
221943_x_at Hs.380953 Ribosomal protein L38 RPL38 chr17q23-q25
200908_s_at Hs.437594 Ribosomal protein, large, P2 RPLP2 chr11p15.5-p15.4
204030_s_at Hs.134665 Schwannomin interacting protein 1 SCHIP1 chr3q25.33
200665_s_at Hs.111779 Secreted protein, acidic, cysteine-rich (osteonectin) SPARC chr5q31.3-q32
217995_at Hs.511251 Sulfide quinone reductase-like (yeast) SQRDL chr15q15
208763_s_at Hs.522074 TSC22 domain family, member 3 TSC22D3 chrXq22.3
202096_s_at Hs.202 Translocator protein (18 kDa) TSPO chr22q13.31
202112_at Hs.440848 von Willebrand factor VWF* chr12p13.3
201368_at Hs.503093 Zinc finger protein 36, C3H type-like 2 ZFP36L2 chr2p22.3-p21
201369_s_at Hs.503093 Zinc finger protein 36, C3H type-like 2 ZFP36L2 chr2p22.3-p21
*Discussed in the text.
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Table 3. Top 50 genes enriched in bone marrow CD34+ CD38– hematopoietic stem cells
Probe set ID UniGene ID Gene title Gene symbol Location
205239_at Hs.645475 Amphiregulin (schwannoma-derived AREG chr4q13-q21
growth factor)
214575_s_at Hs.72885 Azurocidin 1 (cationic antimicrobial protein 37) AZU1 chr19p13.3
218332_at Hs.334370 Brain expressed, X-linked 1 BEX1 chrXq21-q23|Xq22
202095_s_at Hs.514527 Baculoviral IAP repeat-containing 5 (survivin) BIRC5* chr17q25
205950_s_at Hs.23118 Carbonic anhydrase I CA1 chr8q13-q22.1
214315_x_at Hs.515162 Calreticulin CALR chr19p13.3-p13.2
213226_at Hs.58974 Cyclin A2 CCNA2* chr4q25-q31
206488_s_at Hs.120949 CD36 molecule (thrombospondin receptor) CD36 chr7q11.2
218157_x_at Hs.22065 CDC42 small effector 1 CDC42SE1 chr1q21.2
209057_x_at Hs.485471 CDC5 cell division cycle 5-like (S. pombe) CDC5L chr6p21
201131_s_at Hs.461086 Cadherin 1, type 1, E-cadherin (epithelial) CDH1* chr16q22.1
209714_s_at Hs.84113 Cyclin-dependent kinase inhibitor 3 CDKN3 chr14q22
219555_s_at Hs.55028 Centromere protein N CENPN chr16q23.2
205382_s_at Hs.155597 Complement factor D (adipsin) CFD chr19p13.3
214665_s_at Hs.406234 Calcium binding protein P22 CHP chr15q13.3
210140_at Hs.143212 Cystatin F (leukocystatin) CST7 chr20p11.21
204971_at Hs.518198 Cystatin A (stefin A) CSTA chr3q21
201533_at Hs.476018 Catenin (cadherin-associated protein), beta 1, 88kDa CTNNB1* chr3p21
205653_at Hs.421724 Cathepsin G CTSG chr14q11.2
220179_at Hs.302028 Dipeptidase 3 DPEP3 chr16q22.1
214313_s_at Hs.158688 Eukaryotic translation initiation factor 5 B EIF5B chr2q11.2
206871_at Hs.99863 Elastase 2, neutrophil ELA2 chr19p13.3
219672_at Hs.274309 Erythroid associated factor ERAF chr16p11.2
209480_at Hs.409934 Major histocompatibility complex, HLA-DQB1 chr6p21.3
class II, DQ beta 1
207165_at Hs.72550 Hyaluronan-mediated motility HMMR chr5q33.2-qter
receptor (RHAMM)
201163_s_at Hs.479808 Insulin-like growth factor binding protein 7 IGFBP7 chr4q12
213792_s_at Hs.465744 Insulin receptor INSR chr19p13.3-p13.2
219306_at Hs.658939 Kinesin family member 15 KIF15 chr3p21.31
202209_at Hs.111632 LSM3 homolog, U6 small nuclear LSM3 chr3p25.1
RNA associated
213975_s_at Hs.706744 Lysozyme (renal amyloidosis) LYZ chr12q15
217692_at Hs.674373 Mago-nashi homolog 2, MAGOH2 chr17p13.1
proliferation-associated
203948_s_at Hs.458272 Myeloperoxidase MPO* chr17q23.1
206023_at Hs.418367 Neuromedin U NMU chr4q12
218039_at Hs.615092 Nucleolar and spindle associated protein 1 NUSAP1 chr15q15.1
212239_at Hs.132225 Phosphoinositide-3-kinase, regulatory PIK3R1 chr5q13.1
subunit 1 (alpha)
201407_s_at Hs.705383 Protein phosphatase 1, PPP1CB chr2p23
catalytic subunit, beta isoform
203401_at Hs.654581 Phosphoribosyl pyrophosphate synthetase 2 PRPS2 chrXp22.3-p22.2
220051_at Hs.72026 Protease, serine, 21 (testisin) PRSS21 chr16p13.3
207341_at Hs.928 Proteinase 3 PRTN3 chr19p13.3
222077_s_at Hs.708122 Rac GTPase activating protein 1 RACGAP1 chr12q13.13
206851_at Hs.73839 Ribonuclease, RNase A family, 3 RNASE3 chr14q24-q31
214097_at Hs.190968 Ribosomal protein S21 RPS21 chr20q13.3
202917_s_at Hs.416073 S100 calcium binding protein A8 S100A8 chr1q21
220232_at Hs.379191 Stearoyl-CoA desaturase 5 SCD5 chr4q21.22
202083_s_at Hs.464184 SEC14-like 1 (S. cerevisiae) SEC14L1 chr17q25.1-q25.2
204496_at Hs.401843 Striatin, calmodulin binding protein 3 STRN3 chr14q13-q21
206438_x_at Hs.167165 Tectonic family member 2 TCTN2 chr12q24.31
202704_at Hs.653129 Transducer of ERBB2, 1 TOB1 chr17q21
201690_s_at Hs.368433 Tumor protein D52 TPD52 chr8q21
202954_at Hs.93002 Ubiquitin-conjugating enzyme E2C UBE2C chr20q13.12
*Discussed in the text.
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Table 4. Top 50 genes enriched in granulocyte-macrophage colony-stimulating factor–mobilized peripheral blood CD34+
CD38– hematopoietic stem cells
Probe set ID UniGene ID Gene title Gene symbol Location
216356_x_at Hs.458427 BAI1-associated protein 3 BAIAP3 chr16p13.3
212757_s_at Hs.699281 Calcium/calmodulin-dependent protein kinase CAMK2G chr10q22
(CaM kinase) II gamma
213183_s_at Hs.106070 Cyclin-dependent kinase inhibitor 1C (p57KIP2) CDKN1C* chr11p15.5
219400_at Hs.408730 Contactin associated protein 1 CNTNAP1 chr17q21
209432_s_at Hs.522110 cAMP responsive element binding protein 3 CREB3 chr9pter-p22.1
217200_x_at Hs.355264 Cytochrome b-561 CYB561 chr17q11-qter
209178_at Hs.570079 DEAH (Asp-Glu-Ala-His) box polypeptide 38 DHX38 chr16q21-q22.3
208810_at Hs.490745 DnaJ (Hsp40) homolog, subfamily B, member 6 DNAJB6 chr7q36.3
219759_at Hs.591249 Endoplasmic reticulum aminopeptidase 2 ERAP2 chr5q15
211742_s_at Hs.5509 Ecotropic viral integration site 2B EVI2B chr17q11.2
208621_s_at Hs.712548 Ezrin EZR* chr6q25.2-q26
205021_s_at Hs.434286 Forkhead box N3 FOXN3 chr14q31.3
210428_s_at Hs.514590 Hepatocyte growth factor-regulated HGS chr17q25
tyrosine kinase substrate
208569_at Hs.248174 Histone cluster 1, H2ab HIST1H2AB chr6p21.3
221435_x_at Hs.709864 Hydroxypyruvate isomerase homolog (E. coli) HYI chr1p34.2
202439_s_at Hs.460960 Iduronate 2-sulfatase (Hunter syndrome) IDS chrXq28
209342_s_at Hs.656458 Inhibitor of kappa light polypeptide gene IKBKB chr8p11.2
enhancer in B-cells, kinase beta
201626_at Hs.520819 Insulin induced gene 1 INSIG1 chr7q36
209099_x_at Hs.224012 Jagged 1 (Alagille syndrome) JAG1 chr20p12.1
220777_at Hs.189915 Kinesin family member 13A KIF13A chr6p23
203068_at Hs.7764 Kelch-like 21 (Drosophila) KLHL21 chr1p36.31
210671_x_at Hs.138211 Mitogen-activated protein kinase 8 MAPK8 chr10q11.22
202617_s_at Hs.200716 Methyl CpG binding protein 2 (Rett syndrome) MECP2 chrXq28
209636_at Hs.73090 Nuclear factor of kappa light polypeptide gene NFKB2 chr10q24
enhancer in B-cells 2 (p49/p100)
203859_s_at Hs.631841 Paralemmin PALM chr19p13.3
207838_x_at Hs.505806 Pre-B-cell leukemia homeobox interacting protein 1 PBXIP1 chr1q21.3
215175_at Hs.446559 Pecanex homolog (Drosophila) PCNX chr14q24.2
222125_s_at Hs.654944 Hypoxia-inducible factor prolyl 4-hydroxylase PH-4 chr3p21.31
211668_s_at Hs.77274 Plasminogen activator, urokinase PLAU chr10q24
41577_at Hs.45719 Protein phosphatase 1, regulatory (inhibitor) PPP1R16B chr20q11.23
subunit 16B
204304_s_at Hs.614734 Prominin 1 PROM1* chr4p15.32
203149_at Hs.655455 Poliovirus receptor-related 2 (herpesvirus entry mediator B) PVRL2 chr19q13.2
202963_at Hs.709229 Regulatory factor X, 5 (influences HLA class II expression) RFX5 chr1q21
211181_x_at Hs.149261 Runt-related transcription factor 1 RUNX1* chr21q22.3
(acute myeloid leukemia 1; aml1 oncogene)
201250_s_at Hs.706748 Solute carrier family 2 (facilitated glucose transporter), SLC2A1 chr1p35-p31.3
member 1
210993_s_at Hs.656534 SMAD family member 1 SMAD1 chr4q31
212625_at Hs.43812 Syntaxin 10 STX10 chr19p13.13
203753_at Hs.644653 Transcription factor 4 TCF4 chr18q21.1
202085_at Hs.50382 Tight junction protein 2 (zona occludens 2) TJP2 chr9q13-q21
206472_s_at Hs.709205 Transducin-like enhancer of split 3 [E(sp1) homolog, TLE3 chr15q22
Drosophila]
221702_s_at Hs.288912 TM2 domain containing 3 TM2D3 chr15q26.3
219253_at Hs.376722 Transmembrane protein 185B (pseudogene) TMEM185B chr2q14.2
202510_s_at Hs.525607 Tumor necrosis factor, alpha-induced protein 2 TNFAIP2 chr14q32
209295_at Hs.521456 Tumor necrosis factor receptor superfamily, member 10b TNFRSF10B chr8p22-p21
221962_s_at Hs.700368 Ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) UBE2H chr7q32
214792_x_at Hs.25348 Vesicle-associated membrane protein 2 (synaptobrevin 2) VAMP2 chr17p13.1
212171_x_at Hs.73793 Vascular endothelial growth factor A VEGFA* chr6p12
202932_at Hs.194148 V-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 YES1 chr18p11.31-.21
219571_s_at Hs.431471 Zinc finger protein 12 ZNF12 chr7p22.1
219540_at Hs.460645 Zinc finger protein 267 ZNF267 chr16p11.2
*Discussed in the text.
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Figure 2. Unique biological processes in hematopoietic stem cells from different anatomic locations. Selected biological
processes overrepresented by genes enriched or downregulated in CD34+ CD38− cells isolated from (A) cord blood, (B) bone
marrow or (C) peripheral blood. Probe sets differentially expressed (either up or down) in each hematopoietic stem cell sub-
type were subjected to gene set enrichment analysis using the DAVID 2008 Web tool. These categories were selected from the
Biological Process organizing principle in the Gene Ontology project. Categories in red indicate increased expression; those in
green indicate decreased expression. The number of genes, their percentage in cell type-specific probe sets, and p values for
each category significantly (p < 0.05) overrepresented are listed.  NLS = nuclear localization sequence; Ag = antigen.
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of a specific sub-network in CB HSCs (Figures 3B–D),
suggesting their critical roles in maintaining the basic
properties and biological function of CB HSCs.
GATA1 regulates a specific sub-network in CB HSCs
(Figure 3D). This transcription factor was identified as
an erythroid-specific gene essential for erythrocytic dif-
ferentiation at relatively early stages [19]. KLF1 is also
found in this GATA1 sub-network. GATA1 and KLF1
(EKLF) are expressed in precursors and are definitive
differentiation-associated genes [20], while GATA1 also
cooperates with RUNX1 in megakaryocytic differentia-
tion [15]. The presence of GATA1 indicates that HSCs
from CB may contain relatively more lineage-specific
precursors than those isolated from BM or PB.
Genetic networks of BM HSCs
Hepatic growth factor, KRAS, CTNNB1 (β-catenin),
CDH1 (also known as E-cadherin), PAX3 and CDC2
are hub genes in BM HSCs (Figure 4). Hepatic growth
factor and myeloperoxidase, which can both support
self-renewal and keep HSCs in an undifferentiated
state [13], are highly expressed in this subtype of HSC
(Table 3 and Figure 4).
Discussion
Somatic and embryonic stem cells maintain the ability
to self-renew and differentiate and, therefore, possess
great potentials in regenerative medicine for healing tis-
sues that are unable to repair themselves. In this study,
we performed an extensive comparative transcriptome
and gene network analyses of CD34+ HSCs from dif-
ferent sources. The results of these analyses will help to
unravel the riddle of HSCs and contribute to develop-
ments in cell-based therapy.
In addition to identifying specific genes, we also
applied refined computational methods to highlight
key functional networks. There is increasing recognition
that a systematic approach is necessary to view the
overall molecular events responsible for a given biolog-
ical process [21,22]. In this study, we applied systems
biology tools to reveal the functional influences of dif-
ferential gene expression. Knowledge of the enriched
or repressed GO categories in each HSC subtype will
improve understanding of their basic biological prop-
erties and aid their development as potential clinical
applications.
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Figure 3. Genetic networks as a framework for the interpretation of cord blood CD34+ CD38− stem cell biology. (A) Functional
networks composed of multiple genes, some of which (such as MYC, NMYC, GATA1, YWHAZ and JUN) are hub genes with the 
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Cell cycle regulators were upregulated in all three
HSC types, indicating a restricted cell cycle regulation.
However, in BM HSCs, genes involved in mitosis, chro-
mosome condensation and mitotic sister chromatid seg-
regation were more abundant, indicating a relatively
active cell cycle and replication. The downregulation of
cell cycle arrest genes in BM HSCs was consistent with
this theme. Genes involved in cell motility and small
GTPase (Rho) signal transduction were downregulated,
indicating an inert and immobile property of HSCs
inside BM.
In PB HSCs, the regulation of transcription from
RNA polymerase II promoter and the NF-κB and MAP-
KKK cascades were active, indicating the physiological
activities of these stem cells. For example, angiogenesis
and vascular development-related genes were highly ex-
pressed in PB HSCs, which are more motile, suggesting
that they should aid vascular morphogenesis and could
be useful for the treatment of vascular diseases.
Among the three HSC subtypes analyzed, HSCs
from CB appear to provide an excellent source for
transplantation. Genes involved in immunogenic res-
ponses, such as major histocompatibility complex
class I-mediated endogenous antigen processing/pres-
entation and cell defense response, are least active 
in this subtype, suggesting a lower risk of transplant
rejection or graft-versus-host disease. HSCs from PB
or BM, especially those from PB, expressed more genes
associated with active antigen presentation, response
to biotic stimuli, and lymphocyte (B cells) activation,
and would, therefore, be less suitable than CB HSCs in
clinical applications.
Our analyses had certain limitations. The func-
tional networks were mapped based on predetermined
knowledge databases (GO and IPA), in which mole-
cular interactions were established under various phys-
iological or pathologic conditions. It is known that
molecular functions vary according to the cellular and
tissue contexts, and the stemness genes may, there-
fore, not interact in a similar way in human CD34+
cells. Functional analyses are needed for the rigorous
evaluation of individual gene interactions deduced by
in silico modeling.
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